Trade PHVS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Pharvaris N.V. (PHVS) is trading at US$37.74, down 0.26% today as of Sep 9, 16:00 EDT. The company has a market capitalisation of US$2.55B. Over the past 52 weeks, PHVS has traded between US$20.65 and US$43.25. On Syfe you can trade PHVS with $0 commission and add it to your watchlist.
| Previous close | US$37.84 |
|---|---|
| Market cap | US$2.55B |
| 52-week range | US$20.65 – US$43.25 |
| Volume | 1.43M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Pharvaris N.V.
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Year: 2021
Pharvaris N.V. (PHVS) stock is trading at US$37.74, -0.26% from the previous close of US$37.84.
The market cap for Pharvaris N.V. (PHVS) stock is approximately US$2.55B.
The 52-week high for Pharvaris N.V. (PHVS) stock is US$43.25.
The 52-week low for Pharvaris N.V. (PHVS) stock is US$20.65.
Pharvaris N.V. (PHVS) does not currently pay a dividend.
Stay on top of PHVS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
